{
    "key_points": [
        "Pfizer Inc. and BioNTech SE announced positive Phase 2/3 trial results for their COVID-19 vaccine in children aged 5 to 11.",
        "The trial showed a favorable safety profile and robust antibody responses with a 10 \u00b5g dose regimen.",
        "Albert Bourla, CEO of Pfizer, highlighted the need to extend vaccine protection to children, especially with the rise in pediatric cases due to the Delta variant.",
        "Dr. Ugur Sahin, CEO of BioNTech, expressed satisfaction with the data and its consistency with results observed in older populations.",
        "The trial involved 2,268 participants in the age group who received two doses of the 10 \u00b5g vaccine.",
        "Results showed strong immune responses in children, comparable to those in the 16 to 25 age group with the 30 \u00b5g dose.",
        "Pfizer and BioNTech plan to submit data for Emergency Use Authorization (EUA) in the United States and update the EU Conditional Marketing Authorization.",
        "The study is part of a larger trial enrolling children aged 6 months to 11 years to evaluate the vaccine's safety and efficacy.",
        "COMIRNATY (COVID-19 Vaccine, mRNA) by Pfizer and BioNTech is FDA-approved for individuals 16 and older and has EUA for those 12 and older, including a third dose for certain immunocompromised individuals.",
        "Pfizer and BioNTech are committed to sharing further phase 3 trial data and aim for regulatory approvals for younger pediatric populations."
    ],
    "spokespersons": [
        "Albert Bourla (Chairman and Chief Executive Officer, Pfizer)",
        "Dr. Ugur Sahin (CEO and co-founder, BioNTech)"
    ],
    "article_type": "press release",
    "dateline": "NEW YORK AND MAINZ, Germany",
    "audience": "general public",
    "stance": "neutral"
}